» Articles » PMID: 38427120

Research Progress on the Multi-omics and Survival Status of Circulating Tumor Cells

Overview
Journal Clin Exp Med
Specialty General Medicine
Date 2024 Mar 1
PMID 38427120
Authors
Affiliations
Soon will be listed here.
Abstract

In the dynamic process of metastasis, circulating tumor cells (CTCs) emanate from the primary solid tumor and subsequently acquire the capacity to disengage from the basement membrane, facilitating their infiltration into the vascular system via the interstitial tissue. Given the pivotal role of CTCs in the intricate hematogenous metastasis, they have emerged as an essential resource for a deeper comprehension of cancer metastasis while also serving as a cornerstone for the development of new indicators for early cancer screening and new therapeutic targets. In the epoch of precision medicine, as CTC enrichment and separation technologies continually advance and reach full fruition, the domain of CTC research has transcended the mere straightforward detection and quantification. The rapid advancement of CTC analysis platforms has presented a compelling opportunity for in-depth exploration of CTCs within the bloodstream. Here, we provide an overview of the current status and research significance of multi-omics studies on CTCs, including genomics, transcriptomics, proteomics, and metabolomics. These studies have contributed to uncovering the unique heterogeneity of CTCs and identifying potential metastatic targets as well as specific recognition sites. We also review the impact of various states of CTCs in the bloodstream on their metastatic potential, such as clustered CTCs, interactions with other blood components, and the phenotypic states of CTCs after undergoing epithelial-mesenchymal transition (EMT). Within this context, we also discuss the therapeutic implications and potential of CTCs.

Citing Articles

Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review).

Jin Z, Li Y, Yi H, Wang M, Wang C, Du S Int J Oncol. 2025; 66(3).

PMID: 39950314 PMC: 11844340. DOI: 10.3892/ijo.2025.5728.


Advances in circulating tumor cells for early detection, prognosis and metastasis reduction in lung cancer.

Wang X, Bai L, Kong L, Guo Z Front Oncol. 2024; 14:1411731.

PMID: 38974237 PMC: 11224453. DOI: 10.3389/fonc.2024.1411731.

References
1.
Murlidhar V, Reddy R, Fouladdel S, Zhao L, Ishikawa M, Grabauskiene S . Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. Cancer Res. 2017; 77(18):5194-5206. PMC: 5600850. DOI: 10.1158/0008-5472.CAN-16-2072. View

2.
Cheung K, Padmanaban V, Silvestri V, Schipper K, Cohen J, Fairchild A . Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci U S A. 2016; 113(7):E854-63. PMC: 4763783. DOI: 10.1073/pnas.1508541113. View

3.
Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

4.
Buccitelli C, Selbach M . mRNAs, proteins and the emerging principles of gene expression control. Nat Rev Genet. 2020; 21(10):630-644. DOI: 10.1038/s41576-020-0258-4. View

5.
Padillo-Ruiz J, Suarez G, Pereira S, Calero-Castro F, Tinoco J, Marin L . Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients. Cancers (Basel). 2021; 13(24). PMC: 8699156. DOI: 10.3390/cancers13246153. View